dronabinol (BX-1)
/ Bionorica
- LARVOL DELTA
Home
Next
Prev
1 to 14
Of
14
Go to page
1
August 14, 2025
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
(clinicaltrials.gov)
- P2 | N=170 | Completed | Sponsor: Charite University, Berlin, Germany | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Jan 2025
Trial completion • Trial completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
April 11, 2025
DIsCOvER: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P3 | N=109 | Completed | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Active, not recruiting ➔ Completed
Trial completion • Chemotherapy-Induced Nausea and Vomiting • Hepatology • Oncology • Solid Tumor
March 06, 2025
Treating Nightmares in Posttraumatic Stress Disorder with Dronabinol
(clinicaltrials.gov)
- P2 | N=176 | Active, not recruiting | Sponsor: Charite University, Berlin, Germany | Recruiting ➔ Active, not recruiting
Enrollment closed • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
April 16, 2024
DIsCOvER: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P3 | N=109 | Active, not recruiting | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Recruiting ➔ Active, not recruiting
Enrollment closed • Metastases • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor
February 16, 2024
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
(clinicaltrials.gov)
- P2 | N=176 | Recruiting | Sponsor: Charite University, Berlin, Germany | Trial completion date: Jul 2023 ➔ May 2025 | Trial primary completion date: May 2023 ➔ Jan 2025
Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
November 22, 2023
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P3 | N=104 | Recruiting | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024
Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor
September 06, 2023
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P3 | N=104 | Recruiting | Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Trial completion date: Sep 2023 ➔ Mar 2024 | Trial primary completion date: Sep 2022 ➔ Mar 2024
Metastases • Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor • CRP
May 05, 2022
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
(clinicaltrials.gov)
- P2 | N=176 | Recruiting | Sponsor: Charite University, Berlin, Germany | Trial completion date: May 2022 ➔ Jul 2023 | Trial primary completion date: May 2022 ➔ May 2023
Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
June 28, 2021
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P3; N=104; Recruiting; Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie; Trial completion date: Jun 2022 ➔ Sep 2023; Trial primary completion date: Jun 2022 ➔ Sep 2022
Clinical • Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor • CRP
May 05, 2021
BX-1 in Spasticity Due to Multiple Sclerosis
(clinicaltrials.gov)
- P3; N=397; Completed; Sponsor: Bionorica SE; Recruiting ➔ Completed
Clinical • Trial completion • CNS Disorders • Movement Disorders • Multiple Sclerosis
May 04, 2021
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
(clinicaltrials.gov)
- P2; N=176; Recruiting; Sponsor: Charite University, Berlin, Germany; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
July 09, 2020
BX-1 in Spasticity Due to Multiple Sclerosis
(clinicaltrials.gov)
- P3; N=384; Recruiting; Sponsor: Bionorica SE; Trial completion date: Jul 2020 ➔ Feb 2021; Trial primary completion date: Jul 2020 ➔ Feb 2021
Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis
June 26, 2020
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
(clinicaltrials.gov)
- P2; N=176; Not yet recruiting; Sponsor: Charite University, Berlin, Germany
Clinical • New P2 trial • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder
December 24, 2019
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P3; N=140; Recruiting; Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
1 to 14
Of
14
Go to page
1